Evogene (NASDAQ:EVGN) Shares Cross Below Two Hundred Day Moving Average – Should You Sell?

Evogene Ltd. (NASDAQ:EVGN)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.18 and traded as low as $1.04. Evogene shares last traded at $1.10, with a volume of 573,151 shares.

Evogene Price Performance

The stock has a market cap of $5.91 million, a price-to-earnings ratio of -2.20 and a beta of 1.35. The firm has a fifty day moving average of $1.06 and a 200 day moving average of $1.18.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, November 20th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.10. Evogene had a negative return on equity of 75.09% and a negative net margin of 52.33%.The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.65 million.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. Jane Street Group LLC boosted its holdings in Evogene Ltd. (NASDAQ:EVGN) by 58.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,732 shares of the biotechnology company’s stock after acquiring an additional 12,387 shares during the period. Jane Street Group LLC owned 0.63% of Evogene worth $42,000 at the end of the most recent reporting period. 10.40% of the stock is currently owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.